Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Leukemia & Lymphoma
|
February 1, 1995
Anaplastic myeloma
K Zervas, N Constantinou, M Karakantza, et al.
European Journal of Haematology
|
August 1, 1996
Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group
K Zervas, A Pouli, V Perifanis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 16, 2008
Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study
C Lafaras, E Mandala, E Verrou, et al.
World Journal of Gastroenterology
|
April 28, 2007
Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report
D Tzilves, A Gatopoulou, K Zervas, et al.
Hematological Oncology
|
July 2, 2005
The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma
E Hatjiharissi, E Terpos, M Papaioannou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2003
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
K Zervas, M A Dimopoulos, E Hatzicharissi, et al.
Leukemia
|
August 5, 2005
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
E Terpos, D Mihou, R Szydlo, et al.
Leukemia & Lymphoma
|
February 28, 2007
Renal failure in multiple myeloma: incidence, correlations, and prognostic significance
V Eleutherakis-Papaiakovou, A Bamias, D Gika, et al.
European Journal of Haematology
|
February 13, 2001
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group
K Zervas, A Pouli, B Gregoraki, et al.
Leukemia Research
|
March 3, 2009
Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
E Katodritou, V Gastari, E Verrou, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Leukemia & Lymphoma
|
February 1, 1995
Anaplastic myeloma
K Zervas, N Constantinou, M Karakantza, et al.
European Journal of Haematology
|
August 1, 1996
Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group
K Zervas, A Pouli, V Perifanis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 16, 2008
Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study
C Lafaras, E Mandala, E Verrou, et al.
World Journal of Gastroenterology
|
April 28, 2007
Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report
D Tzilves, A Gatopoulou, K Zervas, et al.
Hematological Oncology
|
July 2, 2005
The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma
E Hatjiharissi, E Terpos, M Papaioannou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2003
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
K Zervas, M A Dimopoulos, E Hatzicharissi, et al.
Leukemia
|
August 5, 2005
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
E Terpos, D Mihou, R Szydlo, et al.
Leukemia & Lymphoma
|
February 28, 2007
Renal failure in multiple myeloma: incidence, correlations, and prognostic significance
V Eleutherakis-Papaiakovou, A Bamias, D Gika, et al.
European Journal of Haematology
|
February 13, 2001
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group
K Zervas, A Pouli, B Gregoraki, et al.
Leukemia Research
|
March 3, 2009
Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
E Katodritou, V Gastari, E Verrou, et al.
Page
of 2